Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IFN-gamma-armed adenovirus
- Development stage
- Preclinical
- Lead developer
- University of Minnesota
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
IFN-gamma-armed adenovirus is an oncolytic adenovirus engineered to express the cytokine interferon-gamma (IFN-gamma) within the tumor microenvironment. Developed by researchers at the University of Minnesota, this viro-immunotherapy is designed to treat refractory cancers like pancreatic ductal adenocarcinoma (PDAC). The adenovirus provides direct oncolytic activity by selectively replicating in and lysing cancer cells, while the localized production of IFN-gamma aims to overcome the immunosuppressive tumor microenvironment and enhance anti-tumor immune responses. In preclinical studies, it has been evaluated as a monotherapy and in combination with mesothelin-directed CAR T-cells (meso-CARTs) or other arming transgenes like TGF-beta blockers to reduce fibrosis and improve immune cell infiltration.
- Other names
- IFN-gamma-expressing adenovirusIFN-gamma-armed oncolytic adenovirusAd-IFN-gamma
02
Targets
IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on IFN-gamma-armed adenovirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFN-gamma-armed adenovirus.